OrthoPediatrics Conference Call Summary Company Overview - **Company**: OrthoPediatrics (NasdaqGM: KIDS) - **Industry**: Pediatric orthopedic medical devices Key Points and Arguments New Product Cycle and Super Cycle - OrthoPediatrics is entering a "Super Cycle" with a series of new product launches that will significantly impact financial performance in the coming years [2][3] - The company has expanded its product offerings from 17 systems at the time of going public in 2017 to 87 systems today, including both surgical and bracing options [4][5] Product Innovations - **Trauma and Deformity (T&D)**: This segment accounts for approximately 70% of sales. Recent launches include: - Pediatric nailing platform with femur and tibia products, with a retrograde product in development [7][8] - 3P pediatric plating platform, including the 3P Hip launched in 2025 and additional systems expected in 2026-2028 [19] - **Scoliosis Products**: - Launch of VertiGlide, which allows for growth while correcting curvature, expected to ramp up in 2026 [20][22] - eLLi, a growing spine rod that expands mechanically, with first human trials planned for fall 2026 [23] - **Enabling Technology**: - Playbook, a device for OR efficiency, and iotaMotion, a small robot for cochlear implants, are also in development [37] - **Bracing Products**: OPSB specialty bracing business is expected to grow over 20% annually, with plans to expand clinic locations [50][51] Financial Performance and Cash Flow - Expected free cash flow to be positive in 2026, driven by: - Increased EBITDA from $15 million in 2025 to $25 million in 2026 [45] - More efficient product sets and improved selling prices [46] - Focus on working capital management, including accounts receivable and inventory improvements [46] Competitive Landscape - The company is experiencing reduced competition due to larger companies pulling products from the market, particularly in the trauma and deformity segment, due to EU MDR regulations [62][68] - OrthoPediatrics is positioned to fill the gap left by competitors, with new and improved solutions ready for launch [69] Sales Force and Talent Acquisition - The company has no issues attracting talent, particularly from other specialties, to support its pediatric focus [61] - The competitive landscape has created opportunities for OrthoPediatrics to recruit skilled sales personnel [60] Future Growth and Market Position - OrthoPediatrics aims to serve all segments of pediatric orthopedics, with potential expansion beyond orthopedic products [71] - The company is not currently viewed as a takeover candidate, as it seeks to maintain its unique culture and operational focus [70] Additional Important Information - The 7D navigation device for scoliosis procedures is a significant innovation, offering zero radiation navigation, which is highly favored by surgeons [55][56] - The company is exploring various sales models for its products, including direct sales, consignment, and leasing options [56] This summary encapsulates the key insights from the OrthoPediatrics conference call, highlighting the company's strategic direction, product innovations, financial outlook, and competitive positioning in the pediatric orthopedic market.

Summary of OrthoPediatrics Conference Call Company Overview - **Company Name**: OrthoPediatrics (NasdaqGM: KIDS) - **Industry**: Pediatric Orthopedics - **Focus**: Solely dedicated to pediatric orthopedic solutions, with no involvement in adult orthopedic products [2][3] Key Points and Arguments - **Market Impact**: OrthoPediatrics has helped a cumulative total of 1.3 million children, with a goal to assist over 150,000 children in 2025 and an objective to reach 1 million annually in the future [2][3] - **Unique Product Development**: The company has developed products specifically designed for pediatric patients, addressing unique clinical conditions such as curved bones, which differ significantly from adults [2][3] - **Market Size**: The global pediatric orthopedic market is estimated to be around $6 billion, with significant segments including trauma and deformity, scoliosis, specialty bracing, and enabling technology [5] - **Sales Strategy**: OrthoPediatrics focuses exclusively on children's hospitals in the U.S., which number approximately 300-400, avoiding adult hospitals entirely [5][6] - **Sales Force**: The company employs over 230 sales agents in the U.S. and sells products in over 75 countries, supported by an additional 200 individuals servicing those hospitals [4][5] Product Portfolio and Innovations - **Product Range**: The company has expanded its product offerings from 17 at the time of its IPO in 2017 to over 80 systems currently available [14][22] - **Recent Acquisitions**: Notable acquisitions include Firefly (navigation system for scoliosis), Appifix (internal brace for scoliosis), and Boston O&P (specialty braces and clinics) [9][10][18] - **New Technologies**: Introduction of innovative products such as the VertiGlide system for severe early-onset scoliosis and the DF2 Brace for hip dysplasia, which replaces traditional spica casts [16][17] Financial Performance - **Revenue Growth**: The company has consistently achieved over 20% annual growth, with a projected growth rate of 14% for 2025 [19][21] - **EBITDA Guidance**: For 2025, the company expects adjusted EBITDA between $15 million and $17 million, a significant increase from $8.5 million the previous year [21][22] - **Cash Flow Management**: OrthoPediatrics aims to achieve positive free cash flow in Q4 2025 and break-even in 2026, having reduced cash usage significantly from $40 million two years ago to an expected $20 million this year [23][24] Strategic Focus - **Clinical Education Commitment**: The company emphasizes the importance of clinical education, hosting over 300 training sessions annually for surgeons and clinicians [4][13] - **Market Expansion**: Plans to continue expanding both product offerings and clinic presence, with a focus on specialty bracing, which is projected to grow over 20% annually for the next three to five years [19][18] Conclusion - OrthoPediatrics is positioned as a leader in the pediatric orthopedic market, with a strong commitment to innovation, clinical education, and strategic growth through acquisitions and product development [22][24]